Asia Pacific Acne Medication Market Forecast to 2030 - Regional Analysis - by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel

List of Tables

The Asia Pacific acne medication market was valued at US$ 1,508.26 in 2022 and is expected to reach US$ 2,672.90 million by 2030; it is estimated to register at a CAGR of 7.4% from 2023 to 2030.

Launch of Novel Drugs Boosts Asia Pacific Acne Medication Market

Innovative pharmaceutical developments, including topical and systemic medications, have fundamentally reshaped treatment approaches for acne. In 2024, the Australian Therapeutic Goods Administration (TGA) approved Winlevi (clascoterone) cream 1% from Sun Pharmaceutical of India to treat acne vulgaris in individuals 12 years of age and older. In 2022, Sun Pharmaceutical Industries broadened the scope of its collaboration with Cassiopea with respect to an acne treatment. It has signed extension agreements to the license and supply contracts for WINLEVI (clascoterone) cream 1 percent, enlarging the geographical scope to encompass Australia, New Zealand, Japan, Brazil, Mexico, and Russia. In 2023, Torii Pharmaceutical Co., Ltd. and Nogra Pharma, a clinical-stage biotechnology company creating novel therapeutics for immune-inflammatory-mediated diseases, announced an out-licensing agreement for the development and commercialization of NAC-GED-0507 for the treatment of acne vulgaris in Japan.

Novel drug launches also include advanced formulations with improved efficacy, enhanced safety profiles, and reduced side effects, catering to the evolving needs of individuals seeking effective acne management. According to a statement released in October 2023 by Bausch Health Companies Inc. and its dermatology business-Ortho Dermatologics-the US Food and Drug Administration (FDA) approved the New Drug Application for CABTREO topical gel composed of 1.2%, 0.15%, and 3.1% clindamycin phosphate, adapalene, and benzoyl peroxide, respectively. This is a topical treatment indicated for acne vulgaris in patients aged 12 or older. CABTREO is the first and only topical triple combination acne therapy approved by the FDA, which is offered in a fixed-dose form. The company aims to make this gel available for patients in Q1 2024.

The introduction of novel medications, such as retinoids, anti-androgens, and immune modulators, has further expanded the therapeutic options available for healthcare professionals and individuals dealing with acne. The continuous introduction of new drugs stimulates competition, fosters innovation, and encourages research and development investments within the dermatological pharmaceutical industry. The heightened focus on personalized and targeted treatment approaches for treating acne forms a foundation for the advent of novel drugs to improve patient outcomes and satisfaction. Thus, the launch of novel drugs significantly contributes to the progress of the Asia Pacific acne medication market.

Asia Pacific Acne Medication Market Overview

The Asia Pacific acne medication market is segmented into China, Japan, India, Australia, and South Korea. This region is expected to record the fastest CAGR during the forecast period. The projected acne medication market growth in the region is ascribed to the burgeoning interest of major players in expanding their presence in developing regions and the flourishment of the skincare industry. China's nation's rising disposable income has heightened consumer spending on skincare, contributing to the expansion of the acne medication market size. The increased prevalence of acne, possibly linked to lifestyle changes and environmental factors, has further fueled demand for effective treatments. As Chinese consumers prioritize skincare for their well-being, pharmaceutical companies are introducing innovative formulations to meet this burgeoning demand. Thus, advanced technologies, economic factors, and evolving healthcare priorities are together steering the acne medication market toward unprecedented growth in China.

Asia Pacific Acne Medication Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Acne Medication Market Segmentation

The Asia Pacific acne medication market is segmented based on therapeutic class, formulation, type, acne type, distribution channel, and country.

Based on therapeutic class, the Asia Pacific acne medication market is segmented into retinoids, benzoyl peroxide, antibiotics, salicylic acid, and others. The retinoids segment held the largest share in 2022.

In terms of formulation, the Asia Pacific acne medication market is bifurcated into topical medication and oral medication. The topical medication segment held a larger largest share in 2022.

By type, the Asia Pacific acne medication market is bifurcated into prescription medicine and over-the-counter medicine. The prescription medicine segment held a larger largest share in 2022.

Based on acne type, the Asia Pacific acne medication market is bifurcated into non-inflammatory acne and inflammatory acne. The inflammatory acne segment held a larger share in 2022.

In terms of distribution channel, the Asia Pacific acne medication market is segmented into pharmacies and drug stores, retail stores, and e-commerce. The pharmacies and drug stores segment held the largest share in 2022.

Based on country, the Asia Pacific acne medication market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific acne medication market in 2022.

Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Bausch Health Companies Inc, Galderma SA, Pfizer Inc, GSK Plc, and Viatris Inc are some of the leading companies operating in the Asia Pacific acne medication market.

Product Code: BMIRE00030658

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Acne Medication Market Landscape

4.1 PEST Analysis
4.2 Pricing Analysis of Topical and Oral Medication
4.3 Patient Population Undergoing Acne Treatment

5. Asia Pacific Acne Medication Market - Key Market Dynamics

5.1 Asia Pacific Acne Medication Market - Key Market Dynamics
5.2 Key Market Drivers
- 5.2.1 Increasing Prevalence of Severe Acne
- 5.2.2 Launch of Novel Drugs
5.3 Key Market Restraints
- 5.3.1 Side Effects Associated with Acne Medication
5.4 Key Market Opportunities
- 5.4.1 Individualized Treatment Programs Based on Cutting-Edge Technologies and Data-Driven Strategies
5.5 Future Trends
- 5.5.1 Upsurge in Need for Organic and Natural Treatments
5.6 Impact of Drivers and Restraints:

6. Acne Medication Market - Asia Pacific Market Analysis

7. Asia Pacific Acne Medication Market Analysis - by Therapeutic Class

7.1 Retinoids
- 7.1.1 Overview
- 7.1.2 Retinoids: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Benzoyl Peroxide
- 7.2.1 Overview
- 7.2.2 Benzoyl Peroxide: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Antibiotics
- 7.3.1 Overview
- 7.3.2 Antibiotics: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Salicylic Acid
- 7.4.1 Overview
- 7.4.2 Salicylic Acid: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Others
- 7.5.1 Overview
- 7.5.2 Others: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Acne Medication Market Analysis - by Formulation

8.1 Topical Medication
- 8.1.1 Overview
- 8.1.2 Topical Medication: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
8.2 Oral Medication
- 8.2.1 Overview
- 8.2.2 Oral Medication: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Acne Medication Market Analysis - by Type

9.1 Prescription Medicine
- 9.1.1 Overview
- 9.1.2 Prescription Medicine: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
9.2 Over-the-Counter Medicine
- 9.2.1 Overview
- 9.2.2 Over-the-Counter Medicine: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Acne Medication Market Analysis - by Acne Type

10.1 Non-Inflammatory Acne
- 10.1.1 Overview
- 10.1.2 Non-Inflammatory Acne: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
10.2 Inflammatory Acne
- 10.2.1 Overview
- 10.2.2 Inflammatory Acne: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Acne Medication Market Analysis - by Distribution Channel

11.1 Pharmacies and Drug Stores
- 11.1.1 Overview
- 11.1.2 Pharmacies and Drug Stores: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
11.2 Retail Stores
- 11.2.1 Overview
- 11.2.2 Retail Stores: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
11.3 E-Commerce
- 11.3.1 Overview
- 11.3.2 E-Commerce: Asia Pacific Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Acne Medication Market - Country Analysis

12.1 Asia Pacific
- 12.1.1 Asia Pacific: Acne Medication Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.1 Asia Pacific: Acne Medication Market - Revenue and Forecast Analysis - by Country
  - 12.1.1.2 China
  - 12.1.1.3 China: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.3.1 China: Acne Medication Market Breakdown, by Therapeutic Class
    - 12.1.1.3.2 China: Acne Medication Market Breakdown, by Formulation
    - 12.1.1.3.3 China: Acne Medication Market Breakdown, by Type
    - 12.1.1.3.4 China: Acne Medication Market Breakdown, by Acne Type
    - 12.1.1.3.5 China: Acne Medication Market Breakdown, by Distribution Channel
  - 12.1.1.4 Japan
  - 12.1.1.5 Japan: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.5.1 Japan: Acne Medication Market Breakdown, by Therapeutic Class
    - 12.1.1.5.2 Japan: Acne Medication Market Breakdown, by Formulation
    - 12.1.1.5.3 Japan: Acne Medication Market Breakdown, by Type
    - 12.1.1.5.4 Japan: Acne Medication Market Breakdown, by Acne Type
    - 12.1.1.5.5 Japan: Acne Medication Market Breakdown, by Distribution Channel
  - 12.1.1.6 India
  - 12.1.1.7 India: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.7.1 India: Acne Medication Market Breakdown, by Therapeutic Class
    - 12.1.1.7.2 India: Acne Medication Market Breakdown, by Formulation
    - 12.1.1.7.3 India: Acne Medication Market Breakdown, by Type
    - 12.1.1.7.4 India: Acne Medication Market Breakdown, by Acne Type
    - 12.1.1.7.5 India: Acne Medication Market Breakdown, by Distribution Channel
  - 12.1.1.8 Australia
  - 12.1.1.9 Australia: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.9.1 Australia: Acne Medication Market Breakdown, by Therapeutic Class
    - 12.1.1.9.2 Australia: Acne Medication Market Breakdown, by Formulation
    - 12.1.1.9.3 Australia: Acne Medication Market Breakdown, by Type
    - 12.1.1.9.4 Australia: Acne Medication Market Breakdown, by Acne Type
    - 12.1.1.9.5 Australia: Acne Medication Market Breakdown, by Distribution Channel
  - 12.1.1.10 South Korea
  - 12.1.1.11 South Korea: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.11.1 South Korea: Acne Medication Market Breakdown, by Therapeutic Class
    - 12.1.1.11.2 South Korea: Acne Medication Market Breakdown, by Formulation
    - 12.1.1.11.3 South Korea: Acne Medication Market Breakdown, by Type
    - 12.1.1.11.4 South Korea: Acne Medication Market Breakdown, by Acne Type
    - 12.1.1.11.5 South Korea: Acne Medication Market Breakdown, by Distribution Channel
  - 12.1.1.12 Rest of Asia Pacific
  - 12.1.1.13 Rest of Asia Pacific: Acne Medication Market - Revenue and Forecast to 2030 (US$ Million)
    - 12.1.1.13.1 Rest of Asia Pacific: Acne Medication Market Breakdown, by Therapeutic Class
    - 12.1.1.13.2 Rest of Asia Pacific: Acne Medication Market Breakdown, by Formulation
    - 12.1.1.13.3 Rest of Asia Pacific: Acne Medication Market Breakdown, by Type
    - 12.1.1.13.4 Rest of Asia Pacific: Acne Medication Market Breakdown, by Acne Type
    - 12.1.1.13.5 Rest of Asia Pacific: Acne Medication Market Breakdown, by Distribution Channel

13. Acne Medication Market- Industry Landscape

13.1 Overview
13.2 Growth Strategies in Acne Medication Market
13.3 Organic Growth Strategies
- 13.3.1 Overview
13.4 Inorganic Growth Strategies
- 13.4.1 Overview
13.5 Product Offered by Farmapiel vs Other Companies Acne Products

14. Company Profiles

14.1 Teva Pharmaceutical Industries Ltd
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 Mayne Pharma Group Ltd
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Almirall SA
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Johnson & Johnson
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Sun Pharmaceutical Industries Ltd
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Bausch Health Companies Inc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Galderma SA
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Pfizer Inc
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 GSK Plc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Viatris Inc
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners
15.2 Glossary of Terms